Supreme Court rules in Hikma's favor in 'skinny' label case
The court unanimously ruled that Hikma's generic version of Amarin’s cardiovascular drug Vascepa (icosapent ethyl) does not infringe on the branded drug maker's patents.
Hikma
The court unanimously ruled that Hikma's generic version of Amarin’s cardiovascular drug Vascepa (icosapent ethyl) does not infringe on the branded drug maker's patents.